USL8

USL8 is a preclinical-stage biotechnology company focused on developing first-in-class small molecule inhibitors of Ubiquitin Specific Peptidase 8 (USP8). The company's lead program targets Cushing's disease, a rare endocrine disorder often caused by USP8 mutations in pituitary adenomas that lead to overproduction of ACTH. By selectively inhibiting USP8, USL8 aims to restore normal hormonal balance and provide a targeted therapy for patients with limited treatment options. Beyond endocrinology, the company is exploring the potential of its USP8 inhibitors in oncology, particularly in cancers where USP8 stabilizes key oncogenic drivers. USL8 was founded by leading scientists from Cold Spring Harbor Laboratory and is headquartered in New York.